Anti-GD2 mAb treatment inhibits the mTOR/MAPK signaling pathway in breast cancer cells (42), which results in inhibition of tumor migration and growth, and competes with Siglec-7 for binding to GD2 (38). This evidence concerns the gene MTOR and breast carcinoma.